Clinical & Experimental Metastasis

, Volume 19, Issue 2, pp 145–153

Antiangiogenic and antimetastatic properties of Neovastat (Æ-941), an orally active extract derived from cartilage tissue

  • Éric Dupont
  • Pierre Falardeau
  • Shaker A. Mousa
  • Violetta Dimitriadou
  • Marie-Claude Pepin
  • Taiqi Wang
  • Moulay A. Alaoui-Jamali
Article

DOI: 10.1023/A:1014546909573

Cite this article as:
Dupont, É., Falardeau, P., Mousa, S.A. et al. Clin Exp Metastasis (2002) 19: 145. doi:10.1023/A:1014546909573

Abstract

A novel naturally occurring antiangiogenic agent isolated from cartilage, referred to as Neovastat (Æ-941), was examined for its efficacy against tumor neovascularization and progression. Exposure to Neovastat results in ex ovo antiangiogenic properties in the chorioallantoid membrane of chicken embryo (71% decrease in the angiogenic index as compared to the basic fibroblast growth factor (bFGF) treated control embryos, P<0.0001). Oral administration of Neovastat inhibits bFGF-induced angiogenesis in the Matrigel mouse model (87.5% decrease in hemoglobin as compared to the bFGF-treated control implants, P<0.0001). Neovastat also induces a dose response decrease of lung metastases in the Lewis lung carcinoma model (oral administration; 69.1% of inhibition obtained at the maximal dose of 0.5 ml/day, P<0.0001). Combined with a sub-optimal dose of cisplatinum (2 mg/kg, i.p.), Neovastat (0.5 ml/day) improved the therapeutic index by increasing the antimetastatic efficacy and by exerting a protective activity against cisplatinum-induced body weight loss and myelosuppression. In summary, our experimental data provide evidence of antiangiogenic and antimetastatic properties of Neovastat, following oral administration.

Æ-941antiangiogenesisantimetastasescartilage extractcartilage tissuecisplatinumNeovastat

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Éric Dupont
    • 1
  • Pierre Falardeau
    • 1
  • Shaker A. Mousa
    • 2
  • Violetta Dimitriadou
    • 1
  • Marie-Claude Pepin
    • 1
  • Taiqi Wang
    • 3
  • Moulay A. Alaoui-Jamali
    • 3
  1. 1.Les Laboratoires Æterna IncQuébecCanada
  2. 2.General PharmacologyDuPont Pharmaceuticals Co., Experimental StationWilmingtonUSA
  3. 3.Lady Davis Institute of the Sir Mortimer B. Davis Jewish General Hospital, Department of Medicine and Pharmacology and TherapeuticsMcGill University, MontréalQuébecCanada